Isabel Radke1, Marie-Kristin von Wahlde1, Christoph Schülke2, Joke Tio1. 1. Department of Gynecology and Obstetrics, University Hospital of Münster, Münster, Germany. 2. Department of Radiology, University Hospital of Münster, Münster, Germany.
Abstract
INTRODUCTION: Breast cancer is the most common cancer in women. It frequently metastasizes to the lung, liver, and bones. Due to the improvement of therapeutic strategies and therefore longer patient survival, brain metastases have become more frequent. However, evidence-based therapeutic options of systemic treatment are limited because patients with breast cancer brain metastases are often excluded from clinical trials. CASE PRESENTATION: Here, we show a patient with brain and orbital metastases from a hormone receptor-positive, Her2neu-negative breast cancer that led to one-sided blindness. She was treated with a combination therapy of the CDK4/6 inhibitor ribociclib and the aromatase inhibitor anastrozole and showed a fast and durable response for 9 months with good tolerability of the treatment. CONCLUSION: Systemic treatment with a CDK4/6 inhibitor and endocrine therapy can be considered in breast cancer brain metastases.
INTRODUCTION: Breast cancer is the most common cancer in women. It frequently metastasizes to the lung, liver, and bones. Due to the improvement of therapeutic strategies and therefore longer patient survival, brain metastases have become more frequent. However, evidence-based therapeutic options of systemic treatment are limited because patients with breast cancer brain metastases are often excluded from clinical trials. CASE PRESENTATION: Here, we show a patient with brain and orbital metastases from a hormone receptor-positive, Her2neu-negative breast cancer that led to one-sided blindness. She was treated with a combination therapy of the CDK4/6 inhibitor ribociclib and the aromatase inhibitor anastrozole and showed a fast and durable response for 9 months with good tolerability of the treatment. CONCLUSION: Systemic treatment with a CDK4/6 inhibitor and endocrine therapy can be considered in breast cancer brain metastases.
Authors: L Gerratana; V Fanotto; M Bonotto; S Bolzonello; A M Minisini; G Fasola; F Puglisi Journal: Clin Exp Metastasis Date: 2015-01-29 Impact factor: 5.150
Authors: Chirag G Patil; Katie Pricola; J Manuel Sarmiento; Sachin K Garg; Andrew Bryant; Keith L Black Journal: Cochrane Database Syst Rev Date: 2017-09-25
Authors: Aki Morikawa; Lilly Jordan; Raquel Rozner; Sujata Patil; Adrienne Boire; Elena Pentsova; Andrew D Seidman Journal: Clin Breast Cancer Date: 2016-07-25 Impact factor: 3.225
Authors: Dennis J Slamon; Patrick Neven; Stephen Chia; Peter A Fasching; Michelino De Laurentiis; Seock-Ah Im; Katarina Petrakova; Giulia Val Bianchi; Francisco J Esteva; Miguel Martín; Arnd Nusch; Gabe S Sonke; Luis De la Cruz-Merino; J Thaddeus Beck; Xavier Pivot; Gena Vidam; Yingbo Wang; Karen Rodriguez Lorenc; Michelle Miller; Tetiana Taran; Guy Jerusalem Journal: J Clin Oncol Date: 2018-06-03 Impact factor: 44.544
Authors: Joyce O'Shaughnessy; Katarina Petrakova; Gabe S Sonke; Pierfranco Conte; Carlos L Arteaga; David A Cameron; Lowell L Hart; Cristian Villanueva; Erik Jakobsen; Joseph T Beck; Deborah Lindquist; Farida Souami; Shoubhik Mondal; Caroline Germa; Gabriel N Hortobagyi Journal: Breast Cancer Res Treat Date: 2017-11-21 Impact factor: 4.872
Authors: Paul Cottu; Alistair Ring; Hikmat Abdel-Razeq; Paolo Marchetti; Fatima Cardoso; Javier Salvador Bofill; Miguel Martín; Lakshmi Menon-Singh; Jiwen Wu; Michelino De Laurentiis Journal: Breast Date: 2022-01-31 Impact factor: 4.254